The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

IP-10 Protein Levels Predict Hepatitis C Treatment Outcome

Back to News Homepage

Next

Early Hepatitis C Trial Data Shows INX-189 to Be Effective

Boceprevir Officially Fast-Tracked

January 12, 2011

Print this page

In the U.S. and Europe, Boceprevir’s entrance into the market is being accelerated due to its effectiveness against Hepatitis C.

Merck’s new oral hepatitis C drug boceprevir will receive fast track reviews from both the FDA and the EMA after the regulators decided it marked a major advance in treatment.

01/07/11

The FDA has granted Merck’s investigational protease inhibitor priority review status, a move that could see the drug on the market within six months.

The US regulator’s European counterpart the EMA has also accepted the marketing Merck’s boceprevir application for accelerated assessment.

Continue reading this entire article:
http://www.inpharm.com/news/110107/merck-hepatitis-c-drug-boceprevir-fast-tracked

No Comments - be the first!
Share
Share

Previous

IP-10 Protein Levels Predict Hepatitis C Treatment Outcome

Back to News Homepage

Next

Early Hepatitis C Trial Data Shows INX-189 to Be Effective

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.